Sartorius Stedim Biotech (XPAR:DIM) Long-Term Capital Lease Obligation : €93 Mil (As of Dec. 2023)

View and export this data going back to 1994. Start your Free Trial

What is Sartorius Stedim Biotech Long-Term Capital Lease Obligation?

Sartorius Stedim Biotech's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was €93 Mil.

Sartorius Stedim Biotech's quarterly Long-Term Capital Lease Obligation increased from Jun. 2023 (€90 Mil) to Sep. 2023 (€98 Mil) but then declined from Sep. 2023 (€98 Mil) to Dec. 2023 (€93 Mil).

Sartorius Stedim Biotech's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (€64 Mil) to Dec. 2022 (€91 Mil) and increased from Dec. 2022 (€91 Mil) to Dec. 2023 (€93 Mil).

Sartorius Stedim Biotech Long-Term Capital Lease Obligation Historical Data

The historical data trend for Sartorius Stedim Biotech's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sartorius Stedim Biotech Long-Term Capital Lease Obligation Chart

Sartorius Stedim Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

44.07

47.46

64.00

91.10

93.10

Sartorius Stedim Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															91.10	91.90	90.00	97.90	93.10

Sartorius Stedim Biotech (XPAR:DIM) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Sartorius Stedim Biotech Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Sartorius Stedim Biotech's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Sartorius Stedim Biotech (XPAR:DIM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sartorius Stedim Biotech SA (XPAR:DIM) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

SRTOY:USA SDMHF:USA DIM:Mexico DIMp:UK 0RG8:UK 56S1:Germany

Address

Otto-Brenner-Strasse 20, Goettingen, DEU, 37079

Website

https://www.sartorius.com

Sartorius Stedim Biotech, or SSB, is a leading provider of bioprocessing solutions. Its sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs, and has a focus on single-use technology, or SUT. It is a subsidiary of Sartorius AG, which has a 74% ownership and 85% voting control. The business is geographically diverse.